drugset / Trial / NCT00990756

A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03526299 In Healthy Adult Volunteers

NCT00990756

Phase 1 Completed 24 enrolled Pfizer
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to investigate safety and toleration of multiple inhaled doses as well as the time course of PF-03526299 concentration in the blood following dosing by dry powder inhaler.

Timeline

Start
2009-11
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-03526299 Unknown 1.396 mg Inhaled
Subject PF-03526299 Unknown 4 mg Inhaled

Indications

No indication recorded.